The PAX8 cistrome in epithelial ovarian cancer.
|Authors||Adler, Emily K., Corona, Rosario I., Lee, Janet M., Rodriguez-Malave, Norma, Mhawech-Fauceglia, Paulette, Sowter, Heidi M., Hazelett, Dennis J., Lawrenson, Kate and Gayther, Simon A.|
PAX8 is a lineage-restricted transcription factor that is expressed in epithelial ovarian cancer (EOC) precursor tissues, and in the major EOC histotypes. Frequent overexpression of PAX8 in primary EOCs suggests this factor functions as an oncogene during tumorigenesis, however, the biological role of PAX8 in EOC development is poorly understood. We found that stable knockdown of PAX8 in EOC models significantly reduced cell proliferation and anchorage dependent growth in vitro, and attenuated tumorigenicity in vivo. Chromatin immunoprecipitation followed by next generation sequencing (ChIP-seq) and transcriptional profiling were used to create genome-wide maps of PAX8 binding and putative target genes. PAX8 binding sites were significantly enriched in promoter regions (p < 0.05) and superenhancers (p < 0.05). MEME-ChIP analysis revealed that PAX8 binding sites overlapping superenhancers or enhancers, but not promoters, were enriched for JUND/B and ARNT/AHR motifs. Integrating PAX8 ChIP-seq and gene expression data identified PAX8 target genes through their associations within shared topological association domains. Across two EOC models we identified 62 direct regulatory targets based on PAX8 binding in promoters and 1,330 putative enhancer regulatory targets. SEPW1, which isinvolved inoxidation-reduction,was identified as a PAX8 target gene in both cell line models. While the PAX8 cistrome exhibits a high degree of cell-type specificity, analyses of PAX8 target genes and putative cofactors identified common molecular targets and partners as candidate therapeutic targets for EOC.
|Keywords||Cancer; Ovarian cancer|
|Digital Object Identifier (DOI)||https://doi.org/10.18632/oncotarget.22718|
|Web address (URL)||http://hdl.handle.net/10545/622076|
|Publication dates||28 Nov 2017|
|Publication process dates|
|Deposited||25 Jan 2018, 14:00|
|Accepted||30 Sep 2017|
Archived with thanks to Oncotarget
|Contributors||University of Southern California, Cedars-Sinai Medical Center and University of Derby|
File Access Level
File Access Level
1views this month
1downloads this month